Overview

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Macarena De La Fuente, MD
Treatments:
Imiquimod
Vaccines